BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Limanskiy V, Vyas A, Chaturvedi LS, Vyas D. Harnessing the potential of gene editing technology using CRISPR in inflammatory bowel disease. World J Gastroenterol 2019; 25(18): 2177-2187 [PMID: 31143069 DOI: 10.3748/wjg.v25.i18.2177] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Sundararaman A, Halami PM. Genome editing of probiotic bacteria: present status and future prospects. Biologia. [DOI: 10.1007/s11756-022-01049-z] [Reference Citation Analysis]
2 Poletti M, Arnauts K, Ferrante M, Korcsmaros T. Organoid-based Models to Study the Role of Host-microbiota Interactions in IBD. J Crohns Colitis 2021;15:1222-35. [PMID: 33341879 DOI: 10.1093/ecco-jcc/jjaa257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wang R, Graham S, Sun N, McCarthy D, Peng R, Erickson J, Oconnor L, Zhu X, Wurbel M, Dunstan R, Westmoreland S, Chung N, Ghayur T, Gu J. CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40. PLoS One 2020;15:e0228221. [PMID: 32155151 DOI: 10.1371/journal.pone.0228221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Wu M, Hu N, Du X, Wei J. Application of CRISPR/Cas9 technology in sepsis research. Brief Funct Genomics 2020;19:229-34. [PMID: 32058568 DOI: 10.1093/bfgp/elz040] [Reference Citation Analysis]